Bizengri Side Effects

Generic name: zenocutuzumab

Note: This document provides detailed information about Bizengri.

Applies to zenocutuzumab: intravenous solution Side Effects associated with zenocutuzumab. Some dosage forms listed on this page may not apply specifically to the brand name Bizengri.

Applies to zenocutuzumab: intravenous solution.

General adverse events

The most common adverse events were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities were increased gamma-glutamyl transpeptidase (GGT), decreased hemoglobin, decreased sodium, decreased platelets, increased AST, increased ALT, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased activated partial thromboplastin time (aPTT) and increased bilirubin.^[Ref]

Hematologic

• Very common (10% or more): Decreased hemoglobin (35%), decreased platelets (26%), hemorrhage (up to 23%), decreased leukocytes (21%)
• Uncommon (0.1% to 1%): Myelodysplastic syndrome^[Ref]

Immunologic

• Very common (10% or more): Infusion-related reactions (up to 13%)^[Ref]

Infusion-related reactions (IRR) includes chills, IRR, nausea, cough, diarrhea, back pain, body temperature increased, dyspnea, face edema, fatigue, non-cardiac chest pain, oropharyngeal discomfort, paresthesia, pyrexia, and vomiting.^[Ref]

Musculoskeletal

• Very common (10% or more): Musculoskeletal pain (up to 28%)
• Common (1% to 10%): Traumatic fracture^[Ref]

Metabolic

• Very common (10% or more): Decreased magnesium (up to 28%), increased alkaline phosphatase (up to 31%), decreased sodium (up to 28%), decreased phosphate (26%), decreased potassium (up to 26%), decreased appetite (up to 11%)^[Ref]

Psychiatric

• Very common (10% or more): Anxiety (10%)
• Common (1% to 10%): Agitation^[Ref]

Oncologic

• Uncommon (0.1% to 1%): Tumor pain^[Ref]

Respiratory

• Very common (10% or more): Dyspnea (18%), cough (15%)
• Common (1% to 10%): Interstitial lung disease/pneumonitis, respiratory failure
• Uncommon (0.1% to 1%): Upper respiratory infection, pneumonia^[Ref]

Other

• Very common (10% or more): Fatigue (up to 21%), COVID-19 (up to 18%), edema (up to 13%), pyrexia (up to 10%)
• Uncommon (0.1% to 1%): Urinary tract infection, viral infection, sepsis, cellulitis, acute cholecystitis, lymphadenitis, staphylococcal infection^[Ref]

Renal

• Common (1% to 10%): Increased creatinine
• Uncommon (0.1% to 1%): Acute kidney injury^[Ref]

Cardiovascular

• Common (1% to 10%): Cardiac failure, Grade 2 LVEF
• Uncommon (0.1% to 1%): Tachycardia, pericardial effusion, cardiovascular fatal event, bradycardia, carotid artery stenosis^[Ref]

Dermatologic

• Very common (10% or more): Rash (14%), dry skin (10%)^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (up to 36%), nausea (up to 23%), vomiting (up to 23%), abdominal pain (18%), constipation (15%), abdominal distension (13%), stomatitis (up to 10%)
• Uncommon (0.1% to 1%): Ascites, dysphagia, ileus, gastric obstruction^[Ref]

Further information

Bizengri side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer